Form 4: Corcept Therapeutics Executive Reports Stock Transfers to Custodial Accounts

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports the transfer of common stock to custodial accounts for a child and discloses holdings including unvested restricted stock awards.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the transfer of 233 shares of common stock to custodial accounts for a child on March 20, 2025.
• Following the reported transactions, Robb beneficially owns 10,898 shares indirectly through custodial accounts.
• Robb also directly owns 18,865 shares, including 1,818 shares underlying unvested restricted stock awards granted on June 3, 2024, 503 shares granted on September 3, 2024, 290 shares granted on December 2, 2024, and 292 shares granted on March 3, 2025.
• These restricted stock awards vest on the one-year anniversary of the grant date, contingent upon Robb satisfying certain requirements.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their potential alignment with shareholder interests.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive stock ownership.
• The vesting of restricted stock awards incentivizes the executive to perform in a way that benefits shareholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transfer, Restricted Stock Awards, Custodial Account, Corcept Therapeutics, CORT, Robb Gary Charles, Executive Compensation